Premium
IC‐P‐110: Autotaxin as a CSF Biomarker for Central Dysmetabolism and Alzheimer’s Disease Outcomes
Author(s) -
McLimans Kelsey E.,
Willette Auriel A.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.140
Subject(s) - autotaxin , medicine , endocrinology , biomarker , neuropathology , psychology , alzheimer's disease , oncology , neuroscience , disease , biology , lysophosphatidic acid , biochemistry , receptor
ation with plasma tau levels (190 CN, 197 LMCI, 188 AD). AnANCOVA model was used to assess differences in plasma tau, transformed using rank scores, by diagnosis and correlation models were used to test associations with cognition, dementia severity, and CSF measures. Voxel-based regression methods were utilized to test the relationship between gray matter density and plasma tau levels. Age, gender, APOE ε4 status, and intracranial volume were used as covariates where appropriate. Results:There was a significant difference in plasma tau levels between diagnostic groups (p1⁄40.034; Fig. 1A). Carriers of APOE ε4 had significantly higher plasma tau levels when compared to non-carriers (p1⁄40.013; Fig. 1B). A significant negative association was observed between plasma tau and the ADNI-Memory score (p<0.001, rp1⁄4-0.17), while a significant positive association was observed between plasma tau and CDR-Sum of Boxes (p1⁄40.001, rp1⁄40.14). Negative associations were observed between plasma tau levels and GMdensity in several key brain regions such as the striatum (Fig. 2A) and the hippocampus (Fig. 2B). Significant positive associations were observed between plasma tau and CSF total-tau (t-tau) and phosphorylated-tau (p-tau) across all participants (t-tau: p<0.001, rp1⁄40.22; p-tau: p<0.001, rp1⁄40.2) and within LMCI (t-tau: p1⁄40.001, rp1⁄40.25; p-tau: p1⁄40.002; rp1⁄40.22). Conclusions: These findings suggest that plasma tau levels may be useful in differentiating prodromal AD from controls and may represent a potential accessible and inexpensive biomarker for tracking early stages of AD. IC-P-110 AUTOTAXIN AS A CSF BIOMARKER FOR CENTRAL DYSMETABOLISM ANDALZHEIMER’S DISEASE OUTCOMES Kelsey E. McLimans, Auriel A. Willette, Iowa State University, Ames, IA, USA; 2 National Institute on Aging/National Institutes of Health (NIA/NIH), Baltimore, MD, USA. Contact e-mail: mclimans@iastate.edu